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Abstract
Purpose: Augmented survival of childhood nephroblastoma and neuroblastoma has 
increased long-term side effects such as metabolic syndrome (MetS). Risk stratification 
is difficult after abdominal radiation because waist circumference underestimates 
adiposity. We aimed to develop a strategy for determining MetS in irradiated survivors 
using an integrated biomarker profile and vascular ultrasonography.
Methods: The NCEP-ATPIII MetS-components, 14 additional serum biomarkers and 
9 vascular measurements were assessed in a single-centre cohort of childhood 
nephroblastoma (n = 67) and neuroblastoma (n = 36) survivors and controls (n = 61). 
Multivariable regression models were used to study treatment effects. Principal 
component analysis (PCA) was used to study all biomarkers in a combined analysis, to 
identify patterns and correlations.
Results: After 27.5 years of follow-up, MetS occurred more often in survivors (14%) 
than controls (3%). Abdominal radiotherapy and nephrectomy, to a lesser extent, 
were associated with MetS and separate components and with several biomarker 
abnormalities. PCA of biomarkers revealed a pattern on PC1 from favourable lipid 
markers (HDL-cholesterol, adiponectin) towards unfavourable markers (triglycerides, 
LDL-cholesterol, apoB, uric acid). Abdominal radiotherapy was associated with the 
unfavourable biomarker profile (β = 1.45, P = 0.001). Vascular measurements were not of 
added diagnostic value.
Conclusions: Long-term childhood nephro- and neuroblastoma survivors frequently 
develop MetS. Additional assessment of biomarkers identified in PCA – adiponectin, LDL, 
apoB, and uric acid – may be used especially in abdominally irradiated survivors, to classify 
MetS as alternative for waist circumference. Vascular ultrasonography was not of  
added value.
Introduction
Over the past decades, survival rates of childhood 
nephroblastoma and neuroblastoma have increased to 
respectively ~90% and ~40–95% (strongly dependent 
on stadium) (1, 2). These tumours are of embryonic 
origin, with a peak incidence under the age of 5 years 
and a presentation predominantly in the abdomen. 
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Treatment often consists of a combination of surgery 
(nephrectomy and/or adrenalectomy), radiotherapy 
and/or intensive chemotherapy. Because of increased 
survival rates, long-term side effects, such as adiposity, 
insulin resistance, dyslipidaemia and hypertension, have 
become more prominent, particularly after treatment 
with abdominal radiotherapy (3, 4, 5). These risk factors 
for diabetes mellitus and cardiovascular disease interact 
and cluster together as metabolic syndrome (6, 7, 8).
In order to prevent the development of diabetes 
mellitus and cardiovascular disease, it is important to 
identify survivors at risk of developing (components of) 
MetS and to diagnose and treat them in a timely fashion 
(9). Risk stratification in childhood cancer survivors (CCS) 
with the classic criteria for MetS components can be 
difficult. This is due to the underestimation of adiposity 
by waist circumference, waist-hip ratio and BMI, in 
particular after abdominal radiotherapy has been applied 
(3, 10). Also, because CCS are relatively young, absolute 
occurrence rates of cardio- and cerebrovascular events are 
low, even though they are at higher relative risk (11, 12, 
13, 14).
There is evidence that measurement of (visceral) fat 
by DXA-scan is a better indicator of adiposity and, hence, 
a better predictor for cardiovascular disease (3, 10), but 
this is a costly and time consuming test. Therefore, in 
addition to the serum biomarkers triglycerides and HDL 
cholesterol that are already included in the definition 
of MetS, several other biomarkers have been suggested 
as surrogate markers for development of MetS and 
cardiovascular disease. These additional biomarkers 
include low-density lipoprotein (LDL) cholesterol, 
adiponectin, uric acid, C-reactive protein and cystatin 
C (15, 16, 17). Also, it has been proposed that metabolic 
biomarkers are more clinically useful for risk prediction 
of diabetes and cardiovascular disease when analysed 
as a combination reflecting different pathophysiologic 
pathways, to reveal underlying patterns or clusters of 
dysmetabolic development (18). In addition, vascular 
ultrasound measurements, such as carotid intima media 
thickness (CIMT), pulse pressure amplification (PPA) and 
pulse wave velocity (PWV), have also been proposed as 
surrogate markers for cardiovascular disease (19, 20). 
So far, no studies have reported on the value of these 
additional biomarkers and vascular ultrasound 
measurements in CCS.
The aim of this cross-sectional study was to develop 
a strategy for determining MetS even in abdominally 
irradiated long-term survivors of childhood nephro- and 
neuroblastoma, using an integrated biomarker profile, 
based on principal component analysis and vascular 
ultrasound measurements.
Patients and methods
Patients
Patients were actively recruited as described before (3). 
Briefly, all long-term (5 or more years after treatment) 
adult survivors of childhood nephro- and neuroblastoma 
(except for survivors of neuroblastoma stage 4s who did 
not receive surgery, radiotherapy or chemotherapy), 
treated between 1961 and 2004 in the Erasmus 
MC/Sophia Children’s Hospital, Rotterdam, The 
Netherlands, that visited the late effects outpatient clinic 
regularly were invited to participate in this cross-sectional 
study. The study was approved by the MREC Erasmus 
MC Rotterdam (trial NL2685, study period 2009–2012). 
Survivors were asked to invite potential control subjects 
such as siblings, friends or neighbours, preferably of the 
same sex and within an age range of 5 years. Written 
informed consent was obtained from all participants.
Data collection
Disease and treatment data were obtained from the medical 
records. Detailed data regarding surgery were confirmed 
from the original surgical and pathological reports. 
Information on medication use (statins, antidiabetic, 
antihypertensive), smoking and socio-economic status was 
collected using a self-designed questionnaire. Weight was 
measured with underwear only to the nearest 0.1 kg with 
a standard clinical balance. Height was measured to the 
nearest millimetre using a Harpenden Stadiometer. BMI was 
calculated (weight(kg)/height(cm)2). Waist circumference 
was measured between lower rib and iliac crest to the 
nearest centimetre. Blood pressure was measured with 
the subject in sitting position after an hour of rest on the 
right arm with the Dinamap® Procare and was defined as 
the mean of three measurements. Components of MetS 
were defined using the NCEP-ATPIII classification: waist 
≥102(men)/88(women) cm, triglycerides ≥1.7 mmol/L or 
use of statins, HDL cholesterol ≤1.03(men)/1.29(women) 
mmol/L or use of statins, blood pressure ≥130/≥85 mmHg 
or use of antihypertensives, fasting glucose ≥5.6 mmol/L 
or antidiabetic treatment, with three or more criteria 
required for the diagnosis MetS (6). The occurrence of 
MetS and components in the current study population 
have been previously published (3).
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Laboratory measurements
Fasting venous blood samples were taken before 10:00 h. 
In addition to the biomarkers in the NCEP-ATPIII 
classification, 13 biomarkers were assessed: free fatty acids 
(FFA), apolipoprotein(apo)-A1, apoB, LDL cholesterol 
(measured, not calculated), leptin, adiponectin, 
lipoprotein(a) (Lp(a)), insulin, cystatin C, uric acid, urea, 
creatinine and hsCRP. Homeostasis model assessment 
(HOMA) was used as an estimate of insulin resistance 
and beta-cell function calculated from glucose and 
insulin concentrations (21). Also, antithrombin, 
protein C, protein S, diluted Russell’s viper venom time 
and von Willebrandfactor antigen were measured to 
exclude subjects with possible non-cancer-therapy-
related coagulation problems (results not reported as 
outcome variables).
Vascular ultrasound measurements
Central systolic and diastolic blood pressure were assessed 
with the SphygmoCor (AtCor Medical, Sydney, Australia), 
which calculates aortic blood pressure from brachial 
pulse wave. Brachial and central pulse pressure (PP, the 
difference between systolic and diastolic blood pressure) 
were calculated, as well as pulse pressure amplification 
(PPA, brachial divided by central PP). Measurements of the 
carotid artery were performed with the subject in supine 
position, the head tilted slightly towards the contralateral 
side. After 5 min of rest, diameter of the common carotid 
artery (CCA), carotid intima media thickness (CIMT) 
and distensibility were measured with a duplex scanner 
(operating frequency 7.5 MHz, Pie Medical Imaging, 
Maastricht, The Netherlands) during six non-consecutive 
heartbeats and reported as mean values. Distensibility 
coefficient (DC) was calculated using the following formula: 
(((2000 × distensibility)/diameter)/PP × 133.22) (22). Pulse 
wave velocity (PWV) was also measured with the subject 
in supine position, with the Complior (Alam Medical, 
Saint-Quentin-Fallavier, France), which simultaneously 
records pulse waves at the carotid and femoral arteries 
(PWV = carotid-femoral distance/time delay).
Statistical analysis
Statistical analysis was performed using R version 3.5.1 
(R Foundation for Statistical Computing, Vienna, Austria). 
Baseline characteristics were compared between survivors 
and controls as well as nephroblastoma survivors 
compared to neuroblastoma survivors, using Fisher’s 
exact test and Chi-squared test for categorical variables 
and by bootstrapping the difference in median values for 
continuous variables.
Occurrence of MetS and MetS components was 
compared between survivors and controls using Fisher’s 
exact test and the Chi-squared test, respectively. Serum 
biomarkers and vascular ultrasound measurements 
were compared between survivors and controls by 
bootstrapping the difference in median values, for which 
the 95% CI was calculated with percentiles.
The effect of abdominal radiotherapy and 
nephrectomy on (components of) MetS, the serum 
biomarkers and the vascular parameters was tested 
with univariable logistic and bootstrap linear regression 
models and, when significant, also in multivariable 
regression models, adjusting for age, sex, smoking and 
socio-economic status. There was no need to adjust for 
use of steroids, as these are not administered in treatment 
protocols of these malignancies or for adrenalectomy, 
because this would lead to overcompensation, as we 
previously published (23).
The serum biomarkers were also analysed by principal 
component analysis (PCA), to identify correlations 
and discriminative patterns and to reduce the effects 
of multiple testing. PCA is an unsupervised, combined 
analysis of all biomarkers that explains most of the 
variance in two principal components (PC1 and PC2) 
and the relative contribution of each biomarker to these 
principal components. With this method, the individual, 
unbiased contribution of each biomarker is calculated. 
PCA was performed on the correlation matrix, which 
means that all variables are standardized to Z-scores. 
Missing values were imputed with the median (except for 
cystatin C, which was missing in 15% of participants and 
therefore was predicted with R package mice based on age, 
sex and the other kidney function variables). The effect 
of abdominal radiotherapy and nephrectomy on PC1 and 
PC2 was tested with linear regression models.
For the analyses of serum biomarkers, vascular 
ultrasound measurements and PCA, participants using 
relevant medication were excluded. A P-value <0.05 was 
considered as statistically significant.
Results
Study population
Eighty-eight nephroblastoma survivors were invited to 
participate in the study, of whom 67 (39 males) agreed 
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(76%). Fifty-five neuroblastoma survivors were invited, of 
whom 36 (15 males) agreed to participate (65%). Survivors 
who did not participate were similar to participating 
survivors with respect to baseline characteristics. In 
total, 61 controls were included (33 males), 37 of whom 
were siblings and 24 were partner or friend. Baseline and 
treatment characteristics are depicted in Table 1. Median 
age was 30 and 31.8 years for survivors and controls, 
respectively, and median follow-up time of survivors was 
27.5 years (range 6.4–48.9 years). Systolic and diastolic 
blood pressure were higher among survivors, whereas 
physical activity, smoking behaviour and socio-economic 
status were not significantly different between survivors 
and controls. Within survivors, nephroblastoma survivors 
were older at diagnosis and had been treated more 
often with nephrectomy and abdominal radiotherapy 
(Supplementary Table 1, see section on supplementary 
materials given at the end of this article). None of the 
study participants had experienced a cardiac event or 
stroke at time of inclusion in the study.
Classic MetS components, biomarkers and vascular 
ultrasound measurements, as compared 
to controls
MetS, as defined by the presence of at least three of the 
NCEP-ATPIII criteria, was present in 14 survivors (14%) 
and 2 controls (3%, P = 0.032), as previously described (3). 
Table 1 Baseline characteristics of included survivors and controls.
Survivors Controls Bootstrap 95% CI P-value
Number 103 (67 nephro-, 36 neuroblastoma) 61
Male sex 54 (52.4%) 33 (54.1%) n.a. 0.96c
Age at follow-up (years)a 30.0 (25.2–37.9) 31.8 (23.3–40.0) (−7.2;2.4) 0.33d
Age at diagnosis (years)a 2.3 (0.8–5.0) n.a.
Follow-up timeb (years)a 27.5 (20.1–31.6) n.a.
BMI (kg/m2)a 24.3 (21.3–26.3) 24.2 (22.1–27.2) (−1.8;1.6) 0.84d
Systolic BP (mmHg)a 124 (117–133) 118 (111–126) (0.3;10.0) 0.026d*
Diastolic BP (mmHg)a 76 (72–83) 72 (66–78) (0.7;7.8) 0.012d*
Medication use 0
 Lipid-lowering 4 (3.9%) 2 (3.3%) n.a. 0.30e
 Diabetes 6 (5.8%) n.a. 0.085e
 Antihypertensive 6 (5.8%) n.a. 0.71e
Physical activity scorea 7695 (6390–10,890) 8080 (6465–12,278) (−2947;1264) 0.71d
Smoking n.a. 0.62c
 Non-smoker 62 (60%) 32 (53%)
 Former smoker 15 (14.6%) 10 (16.4%)
 Smoker 26 (25%) 19 (31%)
Socio-economic status n.a. 0.31e
 Low 22 (21.4%) 10 (16.4%)
 Medium 36 (35.0%) 29 (47.5%)
 High 45 (43.7%) 22 (36.1%)
Nephrectomy 74 (71.8%) n.a.
Adrenalectomy 47 (45.6%) n.a.
Abdominal radiotherapy 42 (40.8%) n.a.
 Pancreas  32 (31.1%)
 Flank  17 (17.0%)
Cumulative dose radiotherapy (Gy)a 21 (20–30) n.a.
Chemotherapy 90 (87.4%) n.a.
 Vincristine  65 (63.1%)
 Actinomycine  48 (46.6%)
 Anthracyclines  30 (29.1%)
 Cyclofosfamide  31 (30.1%)
 Cisplatin  7 (6.8%)
 Teniposide  6 (5.8%)
 Dacarbazine  2 (1.9%)
 Ifosfamide  2 (1.9%) 
Corticosteroids 2 (1.9%) n.a.
Significance codes: 0 *** 0.001 ** 0.01 * 0.05.
aPresented as median (IQR); bTime after cessation of treatment; cChi-squared test; dBootstrapped difference in medians; eFisher’s exact test.
BP, blood pressure; n.a., not applicable.
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Thirty-four survivors (33%) revealed at least two MetS 
criteria, compared to 12 controls (20%, P = 0.074). 
Hypertension and treatment for hypertension occurred 
significantly more often in survivors than controls, 
whereas the other MetS components did not differ 
significantly between groups (Table 2).
Triglycerides (∆ = 0.17 mmol/L, P = 0.036), cystatin 
C (∆ = 0.06 mg/L, P = 0.002) and creatinine levels 
(∆ = 5 mg/mmol, P = 0.014) were significantly higher 
in survivors compared to controls (Table 3). The other 
additional biomarkers were not different between 
survivors and controls. All coagulation markers were 
within the reference range in all participants (data 
not shown).
All vascular measurements were similar between 
survivors and controls.
Influence of abdominal radiotherapy and 
nephrectomy on classic MetS components, 
biomarkers and vascular 
ultrasound measurements
Using univariable logistic regression, abdominal 
radiotherapy was associated with occurrence of MetS 
(odds ratio (OR) = 6.04, 95% CI = 2.04–17.89, P = 0.001), 
presence of two or more MetS components (OR = 3.36, 
95% CI = 1.59–7.07, P = 0.001), as well as with all separate 
components of MetS (Table 4). Using multivariable 
regression analysis, adjusting for age, sex, smoking and 
socio-economic status, abdominal radiotherapy remained 
an independent risk factor for MetS occurrence (OR = 15.3, 
95% CI = 3.21–73.36, P < 0.001), occurrence of two or more 
MetS components (OR = 3.23, 95% CI = 1.35–7.73, P = 0.009) 
as well as the MetS components high triglycerides, 
low HDL cholesterol and hypertension. Nephrectomy 
was not a risk factor for MetS occurrence (OR = 2.97, 
95% CI = 0.98–8.97, P = 0.054). Using multivariable 
regression, nephrectomy was a risk factor for having two 
or more MetS components (OR = 2.78, 95% CI = 1.26–6.17, 
P = 0.012), high triglycerides or treatment (OR = 4.68, 
95% CI = 1.66–13.19, P = 0.004) as well as hypertension or 
treatment (OR = 4.82, 95% CI = 2.05–11.29, P < 0.001).
With regard to the biomarkers, abdominally 
irradiated subjects had higher triglycerides, FFA, apoB, 
LDL, cystatin C and urea levels (Supplementary Table 2A). 
Using multivariable linear regression analysis, abdominal 
radiotherapy remained an independent risk factor for 
higher triglycerides (β = 0.57, P = 0.002), higher FFA 
(β = 0.15, P = 0.008) and higher cystatin C (β = 0.08, 
P = 0.039) (Supplementary Table 2B). Nephrectomy was 
associated with higher cystatin C, uric acid, urea and 
creatinine levels (Supplementary Table 2C). Cystatin 
C (β = 0.12, P < 0.001), uric acid (β = 0.05, P = 0.006) and 
creatinine (β = 6.95, P = 0.042) remained significantly 
associated with nephrectomy in multivariable analysis 
(Supplementary Table 2D).
Ultrasonography revealed that abdominally 
irradiated survivors had significantly higher central 
systolic and diastolic blood pressure and PWV and 
lower DC (Supplementary Table 2A). In multivariable 
analysis, the association between abdominal radiation 
and higher central diastolic blood pressure remained 
significant (β = 5.39, P = 0.023) (Supplementary Table 2B). 
After nephrectomy, survivors had higher central systolic 
blood pressure, but this association was not significant 
in linear regression analysis (Supplementary Tables 
2C and D). As peripheral blood pressure was higher 
as well, there was no clear added value of the vascular 
ultrasound measurements.
Principal component analysis of biomarkers
Principal component analysis of the panel of 17 serum 
biomarkers in survivors yielded principal component 1 
Table 2 Occurrence of MetS and components in survivors and controls.
Survivors (n = 103) Controls (n = 61) P-value
Metabolic syndrome (≥3 components) 14% 3% 0.032*a
 ≥2 MetS components 33% 20% 0.074a
 Abdominal obesity (waist circumference ≥102 (men)/ 
88 (women) cm)
8% 11% 0.61b
 High triglycerides (≥1.7 mmol/L) or treatment 23% 10% 0.052b
 Low HDL cholesterol (≤1.03 (men)/1.29 (women) 
mmol/L) or treatment
29% 18% 0.16b
 High blood pressure (≥130/≥85 mmHg) or treatment 35% 15% 0.007**b
 High glucose (≥5.6 mmol/L) or treatment 22% 11% 0.20b
Significance codes: 0 *** 0.001 ** 0.01 * 0.05.
aFisher’s exact test; bChi-squared test.
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with explained variance of 24.2% and a pattern of 
‘favourable lipids’ (high negative loading for HDL and 
adiponectin) towards ‘unfavourable lipids’ (high positive 
loading of triglycerides, apoB and LDL, as well as uric 
acid). Principal component 2 (PC2, orthogonal on PC1) 
explained 14.3% variance, with high negative loading 
reflected by ‘impaired glucose metabolism’ (HOMA and 
glucose (as well as leptin)) and high positive loading 
reflected by ‘kidney disease’ (creatinine and cystatin C 
(as well as HDL)). As all vectors in the biplot originate 
from the centre, high positive and negative loading on 
PC2 are two separate entities, that is, kidney disease is 
not associated with favourable glucose metabolism and 
neither is impaired glucose metabolism with good kidney 
function. This is only applicable to PC1 since one pattern 
– favourable to unfavourable lipids – can be distinguished 
along the whole axis.
The effect of abdominal radiotherapy and 
nephrectomy on the two principal components is 
depicted in Fig. 1. Survivors who received abdominal 
radiotherapy had a higher positive loading on PC1, 
constituting the unfavourable profile (β = 1.45, P = 0.001). 
There was no significant influence of abdominal 
radiation on PC2 (β = 0.14, P = 0.68). Nephrectomy was 
associated with both higher positive loading on PC1 
(unfavourable lipids, β = 1.13, P = 0.015) and PC2 (kidney 
disease, β = 0.75, P = 0.037).
Discussion
This is the first report that describes the value of an 
integrated biomarker profile, defined by principal 
component analysis, and vascular ultrasound 
Table 3 Comparison of serum biomarkers and vascular parameters between survivors and controls.
Variable Survivors (n = 103)a Controls (n = 61)a 95% CIb P-valueb
Biomarkers
 Lipid metabolismc 
  Triglycerides (mmol/L) 0.96 (0.72–1.41) 0.79 (0.63–1.20) (0.01;0.30) 0.036*
  HDL (mmol/L) 1.35 (1.11–1.52) 1.33 (1.14–1.54) (−0.10;0.12) 0.88
  FFA (mmol/L) 0.53 (0.42–0.69) 0.49 (0.35–0.63) (−0.05;0.11) 0.36
  ApoA1 (g/L) 1.35 (1.23–1.53) 1.36 (1.25–1.49) (−0.06;0.07) 0.65
  ApoB (g/L) 0.85 (0.71–1.06) 0.80 (0.68–0.94) (−0.03;0.16) 0.17
  LDL (mmol/L) 2.84 (2.28–3.57) 2.83 (2.25–3.20) (−0.26;0.40) 0.84
  Leptin (ng/mL) 8.10 (4.23–16.15) 7.69 (2.76–13.79) (−2.61;4.33) 0.66
  Adiponectin (µg/mL) 2.75 (1.01–4.29) 2.74 (1.88–4.16) (−1.02;7.49) 0.91
  Lpa (g/L) 0.13 (0.05–0.37) 0.11 (0.06–0.30) (−0.03;0.06) 0.45
 Glucose metabolismd 
  Glucose (mmol/L) 5.0 (4.6–8.7) 4.9 (4.7–5.2) (−0.1;0.3) 0.42
  Insulin (pmol/L) 21.5 (13.0–55.0) 25.0 (13.0–34.0) (−12.0;13.0) 0.86
  HOMA 0.4 (0.4–0.8) 0.5 (0.4–0.6) (−0.1; 0.2) 0.41
 Other MetS-associated biomarkers
  Cystatin C (mg/L) 0.86 (0.81–0.94) 0.80 (0.74–0.86) (0.03;0.11) 0.002**
  Uric acid (mmol/L) 0.31 (0.25–0.40) 0.31 (0.26–0.34) (−0.02; 0.05) 0.35
  Urea (mmol/L) 5.3 (4.6–6.5) 5.1 (4.3–5.8) (−0.2;0.8) 0.21
  Creatinine (mg/mmol) 74 (67–85) 69 (63–78) (1;10) 0.014*
  hsCRP (mg/L) 1.42 (0.55–3.47) 1.27 (0.52–3.57) (−0.62;0.97) 0.46
Vascular parameterse
 Central SBP (mmHg) 115 (105–126) 110 (101–122) (−4;14) 0.28
 Central DBP (mmHg) 76 (71–84) 77 (70–85) (−5;4) 0.68
 Central PP (mmHg) 38 (31–45) 33 (28–44) (−1;10) 0.068
 PP (mmHg) 46 (40–51) 46 (42–50) (−4;2) 0.64
 PPA 1.23 (1.04–1.44) 1.33 (1.07–1.69) (−0.26;0.09) 0.40
 Diameter CCA (mm) 6.38 (5.92–6.83) 6.40 (5.82–6.68) (−0.25;0.33) 0.83
 CIMT (µm) 523 (477–581) 531 (481–586) (−40;21) 0.44
 DC 25.6 (18.4–32.3) 28.3 (19.6–37.6) (−7.2;3.7) 0.27
 PWV (m/s) 6.9 (6.0–8.0) 7.0 (6.3–7.8) (−0.7;0.4) 0.39
Significance codes: 0 *** 0.001 ** 0.01 * 0.05.
aPresented as median (IQR); bBootstrapped difference in medians; cSubjects using lipid-lowering medication excluded (n = 4 survivors); dSubjects with 
diabetes excluded (n = 6 survivors); eSubjects using antihypertensive medication excluded (n = 6 survivors, n = 2 controls).
CCA, common carotid artery; CIMT, carotid intima media thickness; DC, distensibility coefficient; PP, pulse pressure; PPA, pulse pressure amplification; 
PWV, pulse wave velocity; S/DBP, systolic/diastolic blood pressure.
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measurements, to estimate metabolic syndrome in 
long-term survivors of childhood nephroblastoma and 
neuroblastoma, in addition to classic parameters. We show 
that survivors more frequently develop MetS and that 
they have an unfavourable constitution of biomarkers in 
principal component 1 (PC1), particularly after abdominal 
radiotherapy. By using a principal component analysis, 
we could explore new variables better, since this analysis 
identifies individual contribution with no bias of multiple 
testing. This would not have been possible with another 
analysis, such as multiple correlation or regression. This 
unfavourable constitution of biomarkers consisted of a 
cluster of low HDL cholesterol and adiponectin and high 
triglycerides, LDL cholesterol, apoB and uric acid.
Low HDL and high triglycerides are already classic 
components of MetS in the NCEP-ATPIII classification; the 
other biomarkers have been reported as risk predictors for 
MetS and cardiovascular disease in the general population 
as well as in CCS (16, 17, 24, 25, 26). Therefore, we 
propose the addition of adiponectin, LDL, apoB and uric 
acid in a surveillance setting, particularly in abdominally 
irradiated survivors, to classify MetS as alternative for 
waist circumference.
Our suggestion to add biomarkers to the classical 
components of MetS is in line with the recently 
updated dyslipidaemia management guideline from the 
European Society of Cardiology (ESC) and the European 
Atherosclerosis Society (EAS), in which apoB analysis 
is recommended for cardiovascular risk assessment, 
particularly in people with high triglycerides, obesity, 
MetS and diabetes (27). apoB has been reported as a more 
sensitive marker of atherogenicity of cholesterol particles, 
in particular in insulin resistant patients. In those 
subjects, a relative abundance of dense, more atherogenic 
LDL particles can be present, which would be reflected by 
higher apoB levels (28). Uric acid is linked to metabolic 
syndrome in several ways: hyperuricemia contributes 
to the development of hypertension, insulin resistance 
and obesity (24). The observed inverse relation between 
adiponectin and abdominal radiotherapy is of interest, 
as it may suggest that local radiation damage leads to 
decreased endocrine function of the adipose tissue or a 
lower number of fat cells.
Our finding that abdominal radiotherapy is strongly 
associated with the development of MetS components in 
CCS is consistent with other studies and, more specifically, 
caused by radiation damage to the pancreas (29, 30, 31, 
32). Additionally, abdominal radiotherapy can lead to 
underdevelopment of belly fat and musculature and to 
scoliosis. Hence, measurement of waist circumference 
underestimates adiposity. Previously, we reported that 
body composition is more accurately measured in these 
CCS by DXA-scan (3). The proposed use of additional 
biomarkers has the added advantage that this may be a 
cheaper and less burdensome diagnostic tool.
We found a moderate correlation between PC1 score 
and waist circumference in non-abdominally irradiated 
survivors (Pearson’s r = 0.64, substantially higher than the 
Table 4 Uni- and multivariable regression of the effect of abdominal radiotherapy and nephrectomy on MetS and components.
Univariable analysis Multivariable analysisa
OR (s.e.) 95% CI P-value OR (s.e.) 95% CI P-value
The influence of abdominal radiotherapy
 MetS 6.04 (0.554) 2.04;17.89 0.001** 15.3 (0.799) 3.21;73.36 <0.001***
  ≥2 MetS components 3.36 (0.380) 1.59;7.07 0.001** 3.23 (0.445) 1.35;7.73 0.009**
  Abdominal obesity <0.0001 (1659) – 0.99 – – –
  High triglycerides or treatment 5.70 (0.430) 2.45;13.24 <0.001*** 7.01 (0.548) 2.39;20.52 <0.001***
  Low HDL cholesterol or 
treatment
2.39 (0.389) 1.11;5.12 0.025* 2.94 (0.447) 1.23;7.07 0.016*
  High blood pressure or 
treatment
4.24 (0.387) 1.99;9.06 <0.001*** 5.11 (0.478) 2.00;13.02 <0.001***
  High glucose or treatment 2.38 (0.431) 1.02;5.53 0.044* 2.53 (0.514) 0.92;6.93 0.071
The influence of nephrectomy
 MetS 2.97 (0.564) 0.98;8.97 0.054 – – –
  ≥2 MetS components 2.15 (0.354) 1.07;4.29 0.031* 2.78 (0.406) 1.26;6.17 0.012*
  Abdominal obesity 0.41 (0.607) 0.13;1.35 0.14 – –
  High triglycerides or treatment 2.96 (0.426) 1.29;6.82 0.011* 4.68 (0.528) 1.66;13.19 0.004**
  Low HDL cholesterol or treatment 1.22 (0.361) 0.60;2.47 0.59 – – –
  High blood pressure or treatment 3.95 (0.375) 1.89;8.25 <0.001*** 4.82 (0.435) 2.05;11.29 <0.001***
  High glucose or treatment 1.55 (0.413) 0.69;3.48 0.29 – –
Significance codes: 0 *** 0.001 ** 0.01 * 0.05.
aCorrected for age, sex, smoking and socio-economic status.
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correlations of the separate biomarkers) (Supplementary 
Fig. 1), which supports the feasibility of this screening 
strategy. As a next step, to prove accuracy, sensitivity and 
cost-effectiveness of this strategy, replication in larger and 
independent cohorts is needed. Ultimately, for determining 
how the PC1 biomarkers could be incorporated in MetS 
classification, longitudinally collected information on solid 
endpoints (diabetes mellitus, cardio- and cerebrovascular 
morbidity and mortality) is needed.
Another finding was that principal component 2 was 
not of added value in determining MetS in abdominally 
irradiated survivors. By definition, PC2 explains less of the 
variance. Furthermore, there was no single discriminative 
pattern reflecting PC2 score and no difference in PC2 
Figure 1
Biplots of PCA (principal components 1 and 2) of 
serum biomarkers, with the effect of abdominal 
radiotherapy (A) and nephrectomy (B). Score on 
PC1 and PC2 is a Z-score, based on loadings and 
Z-scores of biomarkers. ApoA1, apolipoprotein-A1; 
ApoB, apolipoprotein-B; FFA, free fatty acids; 
HDL, high density lipoprotein cholesterol; 
HOMA, homeostasis model assessment; LDL, low 
density lipoprotein cholesterol; Lpa, lipoprotein(a).
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constitution was observed between abdominally irradiated 
and non-irradiated survivors.
Unexpectedly, the vascular ultrasound measurements 
were neither of evident added value in estimating MetS. 
We did observe some alterations suggestive of central 
arterial stiffness after abdominal radiotherapy: elevated 
central blood pressure and pulse wave velocity (PWV), 
and lower distensibility coefficient (DC); but after 
adjustment for potential covariates, only central blood 
pressure remained significantly associated with abdominal 
radiotherapy. Although central blood pressure is thought 
to better reflect cardiovascular risk as this represents the 
blood pressure in the coronary and cerebral arteries (33), 
we do not estimate this measurement of substantially 
added value, with peripherally measured blood pressure 
already being a classic MetS component. Although 
vascular abnormalities as observed by ultrasound can 
be early signs of MetS and its consequences, there can 
be variation in the development of these consequences, 
and the type of ultrasound patterns can vary as well. 
Therefore, in the aforementioned ESC/EAS dyslipidaemia 
guideline, it is postulated that assessment of arterial 
plaque burden can be considered as a risk modifier in 
individuals at low or moderate cardiovascular risk, in 
addition to standard cardiovascular risk assessment (27). 
We think that it is conceivable that this variation, as 
well as the relatively young age of our study cohort, may 
contribute to this unexpected finding. It could be that 
these vascular ultrasound measurements will be useful at 
an older age for early detection of atherosclerosis, so it 
would be useful to have longitudinal data. The question 
remains whether asymptomatic atherosclerosis detection 
would have implications compared to interventions for 
the other MetS components.
In the separate analysis of the biomarkers, we 
observed elevated cystatine C in abdominally radiated 
survivors, even without elevation of creatinine. This 
discrepant finding may be due to underdeveloped 
abdominal musculature and, if so, suggests that cystatine 
C is a more sensitive marker for assessing renal function 
in abdominally irradiated survivors (34).
The occurrence of MetS in our control group (3%) 
was relatively low, as MetS prevalence in The Netherlands 
at age 30–39 years has been reported as 10–20% (35). 
We confirmed the representativeness of our controls by 
comparing their metabolic profile with other published, 
similar aged, Dutch reference cohorts (36, 37).
Some limitations of the current study merit 
consideration. This was a cross-sectional study, providing 
information at one time point only. As the study 
population was still relatively young, it is anticipated that 
the prevalence of MetS will increase when the survivors 
age. The advantage of diagnosis at younger age is the 
opportunity to intervene timely, to prevent diabetes and 
cardiovascular disease. This is particularly beneficial in 
childhood cancer survivors who received other, direct 
cardiotoxic treatment, such as anthracyclines and 
radiotherapy. Furthermore, we did not have information 
about daily calorie intake and family history of metabolic 
syndrome, diabetes and cardiovascular disease in our 
study population. However, we did take siblings (60% 
of the control group) and partners as control and took 
the assumption that the calorie intake would be rather 
similar since they have a similar background. Family 
history is also most often similar between survivors and 
sibling controls.
Future research may focus on the validation of the 
use of adiponectin, LDL, apoB and uric acid in larger, 
independent cohorts of survivors, with longitudinal 
follow-up. It may also be of interest to study ratios of 
biomarkers that provide additional diagnostic accuracy 
of MetS in the general population, such as triglycerides/
HDL-ratio and apoB-/apo-A1-ratio.
In conclusion, (young-)adult long-term survivors 
of childhood nephroblastoma and neuroblastoma, in 
particular after abdominal radiotherapy, frequently 
have MetS, defined by classic components, but also a 
novel, unfavourable integrated metabolic biomarker 
profile. This is important as the standard measurement 
of waist circumference after abdominal radiation is 
often infeasible in adult CCS. Our findings suggest that 
integrating the additional biomarkers identified in PCA 
– adiponectin, LDL, apoB and uric acid – may be useful 
to assess MetS, particularly in abdominally irradiated 
survivors. In contrast, vascular ultrasound measurements 
do not seem to be of additional value in estimating MetS 
at this relatively young age. Validation of our proposed 
screening strategy will be of importance to elucidate the 
higher risk of MetS, diabetes mellitus and cardiovascular 
disease in CCS, after previous intensive cancer treatment, 
which is still relatively disguised at young age, and to 
identify subgroups at greater risk at an early stage.
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